Food Allergy Research

Report from AAAAI: Poster Snapshots, March 4, 2017

FARE representatives and many FARE-funded researchers are in Atlanta this weekend for the annual meeting of the American Academy of Allergy, Asthma & Immunology. Over 800 studies published by more than 3000 authors are being presented at AAAAI 2017. Thousands of allergists, immunologists, allied health professionals, research scientists and others are attending.

Among the projects featured at Saturday morning’s poster session:

A new mouse model has been identified for peanut allergy. In previous mouse models, systemic reaction could be triggered in an allergen-sensitized mouse by injecting the allergen into the body cavity. In contrast, a sensitized Collaborative Cross mouse experiences a systemic reaction when challenged with food delivered to the stomach, mimicking the events in a human food allergy reaction more closely. In addition, researchers can now look for genetic differences that make the new mouse susceptible to systemic reaction after absorbing food allergen through the gut.

Canadian researchers examining quality of life in children undergoing oral food challenge have found that children with milk or egg allergy score significantly lower on measures of social and dietary limitation than children with peanut or tree nut allergy. This may be because community awareness of milk and egg as life-threatening allergens is lower than for peanut and tree nut, and milk and egg are widely used, making them harder to avoid in public settings. Overall quality-of-life scores were significantly lower for children with egg allergy compared to tree nut allergy.

Higher dose, longer duration peanut sublingual immunotherapy (SLIT) ­ peanut protein dissolved in solution and administered under the patient’s tongue ­ results in more effective desensitization. After four years of peanut SLIT at a maintenance dose of 4 mg peanut protein, 14 patients aged 1 to 11 years tolerated a median cumulative dose of 2900 mg (800-5000 mg). Prior to treatment, the median tolerated dose was 0 mg (0-425 mg). By comparison, a 2-mg maintenance dose over one year raised the median tolerated cumulative dose to 1710 mg.

Stay tuned for more highlights from the AAAAI meeting on our blog!

Leave a Reply